Follow on Google News News By Tag * Major Depressive Disorder * Pharma Market * Market Research * Neurology * Medical Research * More Tags... Industry News News By Place Country(s) Industry News
Follow on Google News | Product Launches and Patent Expiries to Push Major Depressive Disorder Treatment MarketReportstack's latest report forecasts that Major Depressive Disorder market to witness minimal growth by the end of 2023, reaching an estimated $9.7 billion, at a Compound Annual Growth Rate (CAGR) of 0.39%.
By: Reportstack According to the company’s latest report "PharmaPoint: However, forecasts say that the market value will first undergo a decline until 2017, with sales dropping to $7.3 billion. This can be attributed mainly to the expirations of patents for Eli Lilly’s Cymbalta, Otsuka Pharmaceutical/ Toli Koutsokeras, Ph.D., GlobalData's Senior Analyst covering Neurology, says: “Additionally, there are a number of significant needs in the depression therapeutics market that are yet to be addressed. These include the requirement for products that demonstrate improved efficacy, more favorable safety profiles and a rapid onset of antidepressant effects. Ample opportunity therefore exists for players looking to develop and potentially introduce therapies, which can address these unmet needs, into this arena.” There are already seven products in the late-stage pipeline that could enter the MDD market during the forecast period. These include adjunctive therapies, such as Otsuka/Lundbeck’ tedatioxetine and e-Therapeutics’ Koutsokeras continues: “All seven of these pipeline drugs show promise as safer and more efficacious treatments for MDD patients, while GLYX-13 and ETS6103 in particular boast the potential to provide rapid antidepressant effects. “With their ability to address some of the MDD treatment market’s key unmet needs, we believe that these products’ launches could well spark its return to growth in 2018. Other driving factors behind the reversal in its decline will be the increasing uptake of Lundbeck/Takeda’ This report provides an overview of Major Depressive Disorder (MDD), including epidemiology, etiology, pathophysiology, symptoms, diagnosis and current treatment options. The key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the MDD therapeutics market. Complete report available @ http://www.reportstack.com/ Other MDD Market Reports from Reportstack: Major Depressive Disorder - Pipeline Review, H2 2014 (http://www.reportstack.com/ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|